2024
Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples
Liu Y, Yang M, Fraser K, Graham D, Weinreb P, Weihofen A, Hirst W, Cedarbaum J, Pepinsky B. Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. Journal Of Pharmacology And Experimental Therapeutics 2024, 392: 100003. PMID: 39892989, DOI: 10.1124/jpet.124.002199.Peer-Reviewed Original ResearchCentral nervous systemCerebrospinal fluidMeso Scale DiscoveryCentral nervous system compartmentDrug concentrationsA-synCerebrospinal fluid samplesParkinson's diseasePassive immunotherapy approachesSite of actionImmunotherapy approachesLow drug concentrationsImmunotherapy trialsHealthy volunteersSystemic compartmentDrug-target interactionsCSF samplesObserved doseNervous systemTherapeutic targetA-syn levelsClinical samplesTime-dependent bindingComplex formationCross-linking method
2018
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Kumar N, Pizzo M, Nehra G, Wilken-Resman B, Boroumand S, Thorne R. Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. Bioconjugate Chemistry 2018, 29: 3937-3966. PMID: 30265523, PMCID: PMC7234797, DOI: 10.1021/acs.bioconjchem.8b00548.Peer-Reviewed Original ResearchConceptsCentral nervous systemCNS disordersBlood-cerebrospinal fluid barrierTreatment of CNS disordersCentral nervous system disordersPotential treatment strategyTreating CNS disordersPassive immunotherapy approachesBlood-brain barrierImmunotherapy approachesNervous system disordersDrug deliveryPassive immunotherapyTreatment strategiesSystemic circulationFluid barrierTarget antigenSystem disordersDisease-SpecificNervous systemExogenous antibodiesBrain cancerAntibodiesTherapeutic antibody fragmentsDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply